Effect of Qishen Yiqi dripping pills on the classification of ejection fraction in patients with ischaemic heart failure: A prospective cohort study

As a complementary strategy in addition to HF guideline-directed treatments, QSYQ can further improve EF classification, reduce the occurrence rate of the composite endpoint, improve quality of life, and improve the safety profile of patients with IHF. The study protocol is registered with the Chinese Clinical Trial Registry (ChiCTR-ONRC-14,004,407).